By Sherri Oslick —

About
Court Report:  Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.

Genzyme Corp. v. Cobrek Pharmaceuticals, Inc.
1:10-cv-00112; filed January 7, 2009 in the
Northern District of Illinois

Infringement of U.S. Patent Nos. 5,602,116 ("Method
for Treating and Preventing Secondary Hyperparathyroidism," issued
February 11, 1997) and 7,148,211 ("Formulation For Lipophilic Agents,"
issued December 12 2006) following a Paragraph IV certification as part of
Cobrek's filing of an ANDA to manufacture a generic version of plaintiffs'
Hectorol® (doxercalciferol, used to treat secondary hyperparathyroidism in
patients with chronic kidney disease).  View the complaint here.

Cephalon, Inc. et al. v. Watson Pharmaceuticals, Inc. et al.
2:10-cv-00016; filed January 7, 2009 in the
District Court of Nevada

• Plaintiffs:  Cephalon, Inc.; Cephalon France
• Defendants:  Watson Pharmaceuticals, Inc.; Watson
Laboratories Inc.; Watson Pharma Inc.

Cephalon Inc. et al. v. Watson Pharmaceuticals Inc. et al.
1:10-cv-00007; filed January 5, 2010 in the
District Court of Delaware

• Plaintiffs:  Cephalon Inc.; Cephalon France
• Defendants:  Watson Pharmaceuticals Inc.; Watson
Laboratories Inc.; Watson Pharma Inc.

The complaints in these cases are substantially
identical.  Infringement of U.S.
Patent No. 7,132,570 ("Method for the Production of Crystalline Forms of
Optical Enantiomers of Modafinil," issued November 7, 2006) following a
Paragraph IV certification as part of Watson's filing of an ANDA to manufacture
a generic version of Cephalon's Nuvigil® (armodafinil, used to improve
wakefulness in patients with excessive sleepiness associated with obstructive
sleep apnea/hypopnea syndrome, narcolepsy, and shift work sleep disorder).  View the Delaware complaint here.